We propose that both CAPN1 up and downregulation contribute to different aspects of MASLD physiopathology, which seems to depend on the dietary regimen (sucrose vs. high fat diet) as well as the length of the treatment (eight weeks vs more than 16 weeks). This evidence concerns the gene CAPN1 and metabolic dysfunction-associated steatotic liver disease.